Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines

Area of Science:

• Oncology
• Cancer Biology
• Molecular Therapeutics

Background:

• Clear cell sarcoma (CCS) is an aggressive malignancy common in young adults, characterized by high metastasis rates and poor prognosis.
• Developing effective in vitro models is crucial for advancing CCS research and understanding its complex biology.
• This study established novel CCS cell lines from primary and metastatic lesions, alongside healthy patient fibroblasts, to better recapitulate in vivo processes and multistep carcinogenesis.

Purpose of the Study:

• To establish and characterize novel clear cell sarcoma (CCS) cell lines from patient samples.
• To compare the genetic and epigenetic profiles of CCS cells and normal fibroblasts.
• To evaluate the therapeutic potential of a PRMT1 inhibitor in a CCS cell culture model.

Main Methods:

• Established and characterized two CCS cell lines (MUG Lucifer prim and MUG Lucifer met) and isolated patient fibroblasts.
• Utilized light and electron microscopy, soft agar assays, and xenograft applications to assess tumorigenicity and cellular characteristics.
• Analyzed genetic differences via copy number alternation profiles and epigenetic features through arginine methylation using nuclear magnetic resonance spectroscopy.
• Investigated the anti-tumor effects of a PRMT1 inhibitor using cell viability and apoptosis assays in 2D and 3D cultures.

Main Results:

• The established CCS cell lines, MUG Lucifer prim and MUG Lucifer met, exhibited distinct morphological, genetic, and epigenetic profiles reflecting their original tissues.
• Characterization revealed differences that enable the investigation of novel therapeutic strategies, particularly targeting epigenetic modifications.
• A PRMT1 inhibitor demonstrated significant targeted anti-tumor effects on CCS cells, with no impact on normal fibroblasts at the tested concentration (IC50).

Conclusions:

• The developed CCS cell lines and patient-derived fibroblasts provide an ideal in vitro model for exploring CCS biology.
• PRMT1 inhibitors show potential as targeted therapies, inducing apoptosis in tumor cells while sparing normal fibroblasts.
• These findings support the development of tailored therapies for advanced, metastatic CCS, highlighting the efficacy of targeting specific molecular pathways.